Conference Speakers

Dr. Adam Gerber, MD, PhD, is a leading physician-scientist and the Medical & Scientific Director for Critical Care at Octapharma USA. With over a decade of multidisciplinary experience spanning research, industry, and academic medicine, Dr. Gerber specializes in developing innovative therapies for critical care, trauma, and acute lung injury. His expertise in pulmonary and inflammatory biology, combined with his leadership in advancing products from discovery to clinical application, positions him at the forefront of advancing blood substitutes and therapies for acute hemorrhage when traditional blood products are unavailable.

At Octapharma USA, Dr. Gerber provides strategic direction for critical care products, leading new product launches and overseeing medical reviews of regulatory filings. He has initiated multiple academic collaborations for investigator-initiated trials and preclinical research, focusing on therapies that mimic and enhance the plasma, clotting, and platelet functions of blood.

Previously, as Medical Director at Angion Biomedica, he led early development programs targeting rare pulmonary and renal diseases, including idiopathic pulmonary fibrosis. At Columbia University Medical Center, he established a research program identifying novel therapeutic modalities for alpha-1 antitrypsin deficiency, initiating early-phase discovery of small molecule inhibitors of pulmonary inflammation.

He earned his MD and PhD in Neuroscience and Physiology from SUNY Upstate Medical University and completed his residency in Anesthesiology at Columbia University Medical Center. His dedication to improving patient outcomes aligns with the mission of the International Symposium on Blood Substitutes, making him a vital contributor to advancing the science of blood substitutes.